Standard BioTools Reports Third Quarter 2024 Financial Results
Standard BioTools (NASDAQ: LAB) reported Q3 2024 revenue of $45 million, down 5% year-over-year. The company achieved a 50% adjusted EBITDA improvement and 35% net loss improvement year-over-year. Key financial metrics include: consumables revenue up 13%, instruments revenue down 42%, and services revenue flat. The company maintains $368 million in cash and investments. Operating expenses decreased 18.5% to $55 million, while net loss improved to $26.9 million. The company has operationalized $80 million in merger synergies, expected to be fully realized in 2025, and reaffirmed FY2024 revenue guidance of $170-175 million.
Standard BioTools (NASDAQ: LAB) ha riportato entrate del Q3 2024 pari a 45 milioni di dollari, in calo del 5% rispetto all'anno precedente. L'azienda ha ottenuto un miglioramento del 50% dell'EBITDA rettificato e un miglioramento del 35% della perdita netta anno su anno. I principali indicatori finanziari includono: entrate da consumabili in aumento del 13%, entrate da strumenti in calo del 42% e entrate dai servizi stabili. L'azienda mantiene 368 milioni di dollari in liquidità e investimenti. Le spese operative sono diminuite del 18,5% a 55 milioni di dollari, mentre la perdita netta è migliorata a 26,9 milioni di dollari. L'azienda ha concretizzato 80 milioni di dollari in sinergie di fusione, che si prevede saranno completamente realizzate nel 2025, e ha confermato le previsioni di entrate per l'FY2024 pari a 170-175 milioni di dollari.
Standard BioTools (NASDAQ: LAB) reportó ingresos del Q3 2024 de 45 millones de dólares, una disminución del 5% en comparación con el año anterior. La compañía logró una mejora del 50% en EBITDA ajustado y una mejora del 35% en la pérdida neta interanual. Las métricas financieras clave incluyen: ingresos de consumibles en aumento del 13%, ingresos de instrumentos en caída del 42% y servicios estables. La compañía mantiene 368 millones de dólares en efectivo e inversiones. Los gastos operativos disminuyeron un 18,5% a 55 millones de dólares, mientras que la pérdida neta mejoró a 26,9 millones de dólares. La empresa ha operacionalizado 80 millones de dólares en sinergias de fusión, que se espera que se realicen por completo en 2025, y reafirmó la guía de ingresos para el FY2024 de 170-175 millones de dólares.
스탠다드 바이오툴즈(NASDAQ: LAB)는 2024년 3분기 수익으로 4,500만 달러를 보고했으며, 이는 전년 대비 5% 감소한 수치입니다. 이 회사는 조정된 EBITDA가 50% 개선되었고, 순손실이 전년 대비 35% 개선되었습니다. 주요 재무 지표는 다음과 같습니다: 소비재 수익 13% 증가, 기기 수익 42% 감소, 서비스 수익 보합. 이 회사는 현금 및 투자로 3억 6,800만 달러를 유지하고 있습니다. 운영 비용은 5,500만 달러로 18.5% 감소했으며, 순손실은 2,690만 달러로 개선되었습니다. 이 회사는 8,000만 달러의 합병 시너지를 실현했으며, 이는 2025년까지 완전히 실현될 것으로 예상되며, 2024년 FY 수익 목표를 1억 7천만 - 1억 7천5백만 달러로 재확인했습니다.
Standard BioTools (NASDAQ: LAB) a rapporté des revenus de 3T 2024 de 45 millions de dollars, en baisse de 5% par rapport à l'année précédente. L'entreprise a enregistré une amélioration de 50% de l'EBITDA ajusté et une amélioration de 35% de la perte nette d'une année sur l'autre. Les principaux indicateurs financiers incluent : revenus des consommables en hausse de 13%, revenus des instruments en baisse de 42% et revenus des services stables. L'entreprise dispose de 368 millions de dollars en liquidités et investissements. Les dépenses d'exploitation ont diminué de 18,5% pour atteindre 55 millions de dollars, tandis que la perte nette s'est améliorée à 26,9 millions de dollars. L'entreprise a mis en œuvre 80 millions de dollars de synergies de fusion, qui devraient être complètement réalisées d'ici 2025, et a réaffirmé les prévisions de revenus pour l'FY2024 entre 170 et 175 millions de dollars.
Standard BioTools (NASDAQ: LAB) meldete im Q3 2024 Einnahmen von 45 Millionen US-Dollar, was einem Rückgang von 5% im Vergleich zum Vorjahr entspricht. Das Unternehmen erzielte eine Verbesserung des bereinigten EBITDA um 50% und eine Verbesserung des Nettverlustes um 35% im Jahresvergleich. Wichtige Finanzkennzahlen umfassen: Jederumsatz der Verbrauchsmaterialien um 13% gestiegen, der Umsatz mit Instrumenten um 42% gefallen und der Umsatz mit Dienstleistungen bleibt unverändert. Das Unternehmen hält 368 Millionen US-Dollar an Kassenbeständen und Investitionen. Die Betriebskosten sanken um 18,5% auf 55 Millionen US-Dollar, während sich der Nettoloss auf 26,9 Millionen US-Dollar verbesserte. Das Unternehmen hat 80 Millionen US-Dollar an Synergien aus der Fusion operationalisiert, die bis 2025 vollständig realisiert werden sollen, und bekräftigte die Umsatzprognose für das Geschäftsjahr 2024 von 170-175 Millionen US-Dollar.
- 50% improvement in adjusted EBITDA year-over-year
- 35% reduction in net loss year-over-year
- 13% increase in consumables revenue
- 18.5% decrease in operating expenses
- Gross margin improved to 51.7% from 42.5% year-over-year
- $80 million in merger synergies to be realized by 2025
- 5% decline in overall revenue year-over-year
- 42% decrease in instruments revenue
- Net loss of $26.9 million in Q3 2024
- Negative adjusted EBITDA of $14.2 million
- Weakness in China market affecting instrument sales
Insights
The Q3 results show mixed performance with concerning trends. Revenue declined
The company's cost synergy efforts are delivering results, with operating expenses down
Key concerns include continued macro pressures affecting capital equipment sales, especially in China and the path to adjusted EBITDA break-even in 2026 requires sustained execution. The maintained revenue guidance of
The merger integration with SomaLogic appears to be progressing well, with
The shift in revenue composition toward higher-margin consumables and services (
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) today announced unaudited interim financial results for the third quarter ended September 30, 2024.
Recent Highlights:
- Reported third quarter 2024 revenue of
$45 million - Ongoing merger cost synergy realization delivered
50% adjusted EBITDA improvement and35% net loss improvement year-over-year - Operationalized approximately
$80 million in merger synergies, expected to be fully realized in 2025, and reinforcing path to adjusted EBITDA break-even in 2026 - Balance sheet as of September 30, 2024, includes
$368 million cash, cash equivalents, restricted cash and short-term investments
“Powered by Standard BioTools Business System (SBS), we focused our third quarter efforts on driving commercial execution and enhancing overall operating efficiency. Our team delivered sequential top-line improvement and a significant reduction in spend,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. “Last quarter, we announced the acceleration of our anticipated
Mr. Egholm added, “Our focus on operational excellence and profitability is positioning us for sustained value creation once macro pressures ease. At the same time, we’re investing in certain growth levers within our leading multi-omics portfolio while actively pursuing strategic M&A to accelerate our mission toward becoming a diversified leader in the life science tools industry.”
Financial Results Table
| (Unaudited, in millions) | As Reported | |||||||||
| Three Months Ended September 30, 2024 | Nine Months Ended September 30, 2024 | |||||||||
| Revenue | $ | 45.0 | $ | 127.7 | ||||||
| Gross margin | 51.7 | % | 48.8 | % | ||||||
| Non-GAAP gross margin | 56.9 | % | 53.2 | % | ||||||
| Operating expenses | $ | 55.0 | $ | 204.8 | ||||||
| Non-GAAP operating expenses | $ | 39.8 | $ | 137.2 | ||||||
| Operating loss | $ | (31.7 | ) | $ | (142.4 | ) | ||||
| Net loss | $ | (26.9 | ) | $ | (104.8 | ) | ||||
| Adjusted EBITDA | $ | (14.2 | ) | $ | (69.2 | ) | ||||
| Cash, cash equivalents, restricted cash & short-term investments | $ | 367.6 | $ | 367.6 | ||||||
Selected Pro Forma Combined Unaudited Interim Financial Results
The selected 2024 unaudited pro forma financial information combines the Company's financial results for the three- and nine- month periods ended September 30, 2024, and the historical results of SomaLogic for the five-day period ended on January 5, 2024, the closing date of the merger between the Company and Somalogic (the “Merger”). The selected unaudited pro forma financial information for 2023 combines the historical results of the Company and SomaLogic for their respective three- and nine- month periods ended September 30, 2023. See “Unaudited Pro Forma Results” below for discussion of the pro forma financial information.
| (Unaudited, in millions) | Pro Forma Combined | ||||||||||||||
| Three Months Ended September 30, 2024 | Three Months Ended September 30, 2023 | Nine Months Ended September 30, 2024 | Nine Months Ended September 30, 2023 | ||||||||||||
| Revenue | $ | 45.0 | $ | 47.4 | $ | 128.4 | $ | 141.0 | |||||||
| Gross margin | 51.7 | % | 42.5 | % | 47.5 | % | 43.9 | % | |||||||
| Non-GAAP gross margin | 56.9 | % | 51.7 | % | 53.2 | % | 52.2 | % | |||||||
| Operating expenses | $ | 55.0 | $ | 67.4 | $ | 208.1 | $ | 214.7 | |||||||
| Non-GAAP operating expenses | $ | 39.8 | $ | 52.7 | $ | 137.2 | $ | 175.7 | |||||||
| Operating loss | $ | (31.7 | ) | $ | (47.3 | ) | $ | (147.2 | ) | $ | (152.8 | ) | |||
| Net loss | $ | (26.9 | ) | $ | (41.2 | ) | $ | (134.6 | ) | $ | (109.0 | ) | |||
| Adjusted EBITDA | $ | ( 14.2 | ) | $ | (28.2 | ) | $ | (68.9 | ) | $ | (102.0 | ) | |||
- Revenue was
$45.0 million in the third quarter of 2024, down5% year-over-year:- Consumables revenue was
$14.0 million in the third quarter of 2024, up13% year-over-year. Consumables revenue grew on the strength of assay kits sales to SomaScan authorized sites and the Illumina early access program. - Instruments revenue was
$5.6 million in the third quarter of 2024, down42% year-over-year. Instrument revenue was impacted by capital constrained end-markets globally with particular weakness in China. - Services revenue, which includes both Lab Services and Field Services, was
$24.4 million in the third quarter of 2024, flat year over year. Services benefited from the favorable timing of large SomaScan customer projects that shifted out of the second quarter into the third quarter, partially offset by lower installation services from lower instrument sales.
- Consumables revenue was
- Gross margins in the third quarter of 2024 were
51.7% , versus42.5% in the third quarter of 2023; and non-GAAP gross margins in the third quarter of 2024 were56.9% , versus51.7% in the third quarter of 2023. Gross margins were impacted by positive mix in the third quarter and continued incremental efficiency gains from SBS.
- Operating expenses in the third quarter of 2024 was
$55 million , a decrease of$12.5 million , or down18.5% , compared to the third quarter of 2023, and non-GAAP operating expenses, which exclude merger-related costs, stock-based compensation, and restructuring charges, was$39.8 million , a decrease of$12.8 million , or down24% , compared to the third quarter of 2023. The decrease in operating expenses is a result of ongoing realization of merger cost synergies as previously disclosed, a bonus accrual reduction in line with our full year expectations, as well as continued productivity gains from SBS.
- Net loss for the third quarter of 2024 was
$26.9 million , compared to a net loss of$41.2 million in the third quarter of 2023, representing an improvement of$14.3 million or34.6% , while adjusted EBITDA for the third quarter of 2024 was a loss of$14.2 million , versus an adjusted EBITDA loss of$28.2 million in 2023, an improvement of$14 million , or49.6% .
FY 2024 Revenue Outlook
Following its third quarter 2024 results, the Company has reiterated its full year 2024 revenue guidance to a range of
Third quarter 2024 Earnings Conference Call Information
Standard BioTools will host a conference call and webcast on October 30, 2024 at 1:30 p.m. PT (4:30 p.m. ET) to discuss third quarter 2024 financial results. Live audio of the webcast will be available online along with an archived version of the webcast under the Events & Presentations page of the Company’s website.
Individuals interested in listening to the conference call may do so by dialing:
US domestic callers: 1-888-346-3970
Outside US callers: 1-412-902-4297
Use of Non-GAAP Financial Information
Standard BioTools has presented certain financial information in accordance with U.S. GAAP and on a non-GAAP basis. The non-GAAP financial measures included in this press release are non-GAAP gross margin, non-GAAP operating expenses, and adjusted EBITDA. Management uses these non-GAAP financial measures, in addition to GAAP financial measures, as a measure of operating performance because the non-GAAP financial measures do not include the impact of items that management does not consider indicative of the Company’s core operating performance. Management believes that non-GAAP financial measures, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the Company’s core operating results. Management uses non-GAAP measures to compare the Company’s performance relative to forecasts and strategic plans and to benchmark the company’s performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under U.S. GAAP. Standard BioTools encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release.
Unaudited Pro Forma Results
The unaudited pro forma financial information for nine months ended September 30, 2024, combines the Company's financial results for the nine months ended September 30, 2024, and the historical results of SomaLogic for the 5-day period ended on the January 5, 2024, the closing date of the Merger. The unaudited pro forma financial information for the three and nine months ended September 30, 2023, combines the historical results of the Company and SomaLogic for their respective three- and nine-month periods ended September 30, 2023. The pro forma financial information for all periods presented has been adjusted to include certain nonrecurring impacts associated with the Merger, including the bargain purchase gain and transaction costs.
The unaudited pro forma financial information for all periods presented includes the business combination accounting effects resulting from the Merger, mainly including adjustments to reflect additional amortization expense from acquired intangible assets, adjustments to stock-based compensation expense, and additional depreciation expense from the acquired property and equipment. The unaudited pro forma financial information is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved if the acquisitions had taken place on January 1, 2023. The results of SomaLogic have been consolidated with the Company's results since the closing date of the Merger.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding future financial and business performance, including with respect to future revenue, net loss and adjusted EBITDA; operational and strategic plans; deployment of capital; market and growth opportunity and potential; and the potential to realize the expected benefits and synergies of the Merger, including the potential for it to drive long-term profitable growth. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, but not limited to, risks that the anticipated benefits and synergies of the Merger and the integration of SomaLogic, including the potential for it to drive long-term profitable growth, may not be fully realized or may take longer to realize than expected; risks that the Company may not realize expected cost savings from the Merger , including the anticipated decrease in operational expenses, at the levels it expects; possible integration, restructuring and transition-related disruption, including through the loss of customers, suppliers, and employees and adverse impacts on the Company’s development activities and results of operation; integration and restructuring activities, including customer and employee relations, management distraction, and reduced operating performance; risks that internal and external costs required for ongoing and planned activities may be higher than expected, which may cause the Company to use cash more quickly than it expects or change or curtail some of the Company’s plans, or both; risks that the Company’s expectations as to expenses, cash usage, and cash needs may prove not to be correct for other reasons such as changes in plans or actual events being different than our assumptions; changes in the Company’s business or external market conditions; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; interruptions or delays in the supply of components or materials for, or manufacturing of, the Company’s products; reliance on sales of capital equipment for a significant proportion of revenues in each quarter; seasonal variations in customer operations; unanticipated increases in costs or expenses; continued or sustained budgetary, inflationary, or recessionary pressures; uncertainties in contractual relationships; reductions in research and development spending or changes in budget priorities by customers; uncertainties relating to the Company’s research and development activities, and distribution plans and capabilities; potential product performance and quality issues; risks associated with international operations; intellectual property risks; and competition. For information regarding other related risks, see the “Risk Factors” section of the Company’s annual report on Form 10-K filed with the SEC on March 1, 2024, and in the Company’s other filings with the SEC. These forward-looking statements speak only as of the date hereof. The Company disclaims any obligation to update these forward-looking statements except as may be required by law.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq: LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
For Research Use Only. Not for use in diagnostic procedures.
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.
Investor Contact
David Holmes
Gilmartin Group LLC
ir@standardbio.com
| STANDARD BIOTOOLS INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share amounts) (Unaudited) | |||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||
| Revenue: | |||||||||||||||||
| Product revenue | $ | 19,593 | $ | 18,711 | $ | 65,348 | $ | 57,814 | |||||||||
| Services revenue | 24,438 | 6,566 | 59,518 | 19,268 | |||||||||||||
| Collaboration and other revenue | 938 | 90 | 2,848 | 1,070 | |||||||||||||
| Total revenue | 44,969 | 25,367 | 127,714 | 78,152 | |||||||||||||
| Cost of revenue: | |||||||||||||||||
| Cost of product revenue | 8,159 | 11,403 | 33,142 | 33,276 | |||||||||||||
| Cost of services revenue | 13,536 | 2,810 | 32,115 | 7,783 | |||||||||||||
| Cost of collaboration and other revenue | 13 | — | 100 | — | |||||||||||||
| Total cost of revenue | 21,708 | 14,213 | 65,357 | 41,059 | |||||||||||||
| Gross profit | 23,261 | 11,154 | 62,357 | 37,093 | |||||||||||||
| Operating expenses: | |||||||||||||||||
| Research and development | 13,156 | 6,370 | 48,358 | 19,039 | |||||||||||||
| Selling, general and administrative | 34,403 | 22,292 | 119,020 | 66,187 | |||||||||||||
| Restructuring and related charges | 2,341 | 1,998 | 12,374 | 5,415 | |||||||||||||
| Transaction and integration expenses | 5,079 | 1,666 | 25,024 | 1,666 | |||||||||||||
| Total operating expenses | 54,979 | 32,326 | 204,776 | 92,307 | |||||||||||||
| Loss from operations | (31,718 | ) | (21,172 | ) | (142,419 | ) | (55,214 | ) | |||||||||
| Bargain purchase gain | — | — | 25,213 | — | |||||||||||||
| Interest income, net | 3,941 | 340 | 13,559 | 656 | |||||||||||||
| Other income (expense), net | 957 | (115 | ) | (865 | ) | 292 | |||||||||||
| Loss before income taxes | (26,820 | ) | (20,947 | ) | (104,512 | ) | (54,266 | ) | |||||||||
| Income tax benefit (expense) | (118 | ) | (50 | ) | (301 | ) | (614 | ) | |||||||||
| Net loss | $ | (26,938 | ) | $ | (20,997 | ) | $ | (104,813 | ) | $ | (54,880 | ) | |||||
| Induced conversion of redeemable preferred stock | — | — | (46,014 | ) | — | ||||||||||||
| Net loss attributable to common stockholders | $ | (26,938 | ) | $ | (20,997 | ) | $ | (150,827 | ) | $ | (54,880 | ) | |||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.07 | ) | $ | (0.27 | ) | $ | (0.44 | ) | $ | (0.69 | ) | |||||
| Shares used in computing net loss per share attributable to common stockholders, basic and diluted | 371,538 | 79,152 | 346,093 | 78,967 | |||||||||||||
| STANDARD BIOTOOLS INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited) | ||||||||
| September 30, 2024 | December 31, 2023 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 210,647 | $ | 51,704 | ||||
| Short-term investments | 155,683 | 63,191 | ||||||
| Accounts receivable, net | 35,317 | 19,660 | ||||||
| Inventory | 42,644 | 20,533 | ||||||
| Prepaid expenses and other current assets | 9,316 | 3,127 | ||||||
| Total current assets | 453,607 | 158,215 | ||||||
| Inventory, non-current | 17,949 | — | ||||||
| Royalty receivable, non-current | 3,388 | — | ||||||
| Property and equipment, net | 41,982 | 24,187 | ||||||
| Operating lease right-of-use asset, net | 30,264 | 30,663 | ||||||
| Other non-current assets | 4,640 | 2,285 | ||||||
| Acquired intangible assets, net | 23,367 | 1,400 | ||||||
| Goodwill | 106,342 | 106,317 | ||||||
| Total assets | $ | 681,539 | $ | 323,067 | ||||
| LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 10,926 | $ | 9,236 | ||||
| Accrued liabilities | 31,686 | 21,019 | ||||||
| Operating lease liabilities, current | 6,122 | 4,323 | ||||||
| Deferred revenue, current | 13,436 | 11,607 | ||||||
| Deferred grant income, current | 3,532 | 3,612 | ||||||
| Term loan, current | — | 5,000 | ||||||
| Convertible notes, current | 54,913 | 54,530 | ||||||
| Total current liabilities | 120,615 | 109,327 | ||||||
| Convertible notes, non-current | 299 | 569 | ||||||
| Term loan, non-current | — | 3,414 | ||||||
| Deferred tax liability | 841 | 841 | ||||||
| Operating lease liabilities, non-current | 28,140 | 30,374 | ||||||
| Deferred revenue, non-current | 32,682 | 3,520 | ||||||
| Deferred grant income, non-current | 8,119 | 10,755 | ||||||
| Other non-current liabilities | 1,510 | 1,065 | ||||||
| Total liabilities | 192,206 | 159,865 | ||||||
| Mezzanine equity: | ||||||||
| Redeemable preferred stock | — | 311,253 | ||||||
| Total stockholders’ equity (deficit) | 489,333 | (148,051 | ) | |||||
| Total liabilities, mezzanine equity and stockholders’ equity (deficit) | $ | 681,539 | $ | 323,067 | ||||
| STANDARD BIOTOOLS INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited) | |||||||||
| Nine Months Ended September 30, | |||||||||
| 2024 | 2023 | ||||||||
| Operating activities | |||||||||
| Net loss | $ | (104,813 | ) | $ | (54,880 | ) | |||
| Bargain purchase gain | (25,213 | ) | — | ||||||
| Stock-based compensation expense | 24,262 | 9,648 | |||||||
| Amortization of acquired intangible assets | 3,533 | 8,400 | |||||||
| Depreciation and amortization | 9,375 | 2,874 | |||||||
| Accretion of discount on short-term investments, net | (6,303 | ) | (321 | ) | |||||
| Non-cash lease expense | 4,348 | 2,885 | |||||||
| Provision for excess and obsolete inventory | 1,991 | 963 | |||||||
| Change in fair value of warrants | (474 | ) | — | ||||||
| Other non-cash items | 1,111 | 611 | |||||||
| Changes in assets and liabilities, net | (37,212 | ) | 594 | ||||||
| Net cash used in operating activities | (129,395 | ) | (29,226 | ) | |||||
| Investing activities | |||||||||
| Cash and restricted cash acquired in merger | 280,033 | — | |||||||
| Purchases of short-term investments | (226,612 | ) | (55,857 | ) | |||||
| Proceeds from sales and maturities of investments | 289,000 | 91,964 | |||||||
| Purchases of property and equipment | (4,973 | ) | (2,753 | ) | |||||
| Net cash provided by investing activities | 337,448 | 33,354 | |||||||
| Financing activities | |||||||||
| Repayment of term loan and convertible notes | (8,192 | ) | (833 | ) | |||||
| Payment of term loan fee | (545 | ) | — | ||||||
| Repurchase of common stock | (40,490 | ) | (5,240 | ) | |||||
| Proceeds from ESPP stock issuance | 425 | 326 | |||||||
| Payments for taxes related to net share settlement of equity awards and other | (414 | ) | (139 | ) | |||||
| Proceeds from exercise of stock options | 1,120 | 80 | |||||||
| Net cash used in financing activities | (48,096 | ) | (5,806 | ) | |||||
| Effect of foreign exchange rate fluctuations on cash and cash equivalents | (518 | ) | (196 | ) | |||||
| Net increase in cash, cash equivalents and restricted cash | 159,439 | (1,874 | ) | ||||||
| Cash, cash equivalents and restricted cash at beginning of period | 52,499 | 82,324 | |||||||
| Cash, cash equivalents and restricted cash at end of period | $ | 211,938 | $ | 80,450 | |||||
| Cash, cash equivalents, and restricted cash consists of: | |||||||||
| Cash and cash equivalents | $ | 210,647 | $ | 79,655 | |||||
| Restricted cash | 1,291 | 795 | |||||||
| Total cash, cash equivalents and restricted cash | $ | 211,938 | $ | 80,450 | |||||
| STANDARD BIOTOOLS INC. REVENUE AND NON-GAAP PRO FORMA COMBINED REVENUE (In thousands) (Unaudited) | |||||||||||||
| As Reported | |||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||
| Product revenue: | |||||||||||||
| Instruments | $ | 5,586 | $ | 9,002 | $ | 19,959 | $ | 26,512 | |||||
| Consumables | 14,007 | 9,709 | 45,389 | 31,302 | |||||||||
| Total product revenue | 19,593 | 18,711 | 65,348 | 57,814 | |||||||||
| Service revenue: | |||||||||||||
| Lab services | 18,247 | 114 | 40,780 | 564 | |||||||||
| Field services | 6,191 | 6,452 | 18,738 | 18,704 | |||||||||
| Total service revenue | 24,438 | 6,566 | 59,518 | 19,268 | |||||||||
| Product and service revenue | 44,031 | 25,277 | 124,866 | 77,082 | |||||||||
| Collaboration and other revenue | 938 | 90 | 2,848 | 1,070 | |||||||||
| Total revenue | $ | 44,969 | $ | 25,367 | $ | 127,714 | $ | 78,152 | |||||
| Non-GAAP Pro Forma | |||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||
| Product revenue: | |||||||||||||
| Instruments | $ | 5,586 | $ | 9,712 | $ | 19,959 | $ | 27,683 | |||||
| Consumables | 14,007 | 12,417 | 45,389 | 37,644 | |||||||||
| Total product revenue | 19,593 | 22,129 | 65,348 | 65,327 | |||||||||
| Service revenue: | |||||||||||||
| Lab services | 18,247 | 17,980 | 41,384 | 53,446 | |||||||||
| Field services | 6,191 | 6,452 | 18,738 | 18,704 | |||||||||
| Total service revenue | 24,438 | 24,432 | 60,122 | 72,150 | |||||||||
| Product and service revenue | 44,031 | 46,561 | 125,470 | 137,477 | |||||||||
| Collaboration and other revenue | 938 | 854 | 2,889 | 3,570 | |||||||||
| Total revenue | $ | 44,969 | $ | 47,415 | $ | 128,359 | $ | 141,047 | |||||
| STANDARD BIOTOOLS INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (In thousands) (Unaudited) | |||||||||||||||||
| ITEMIZED RECONCILIATION OF GROSS PROFIT TO NON-GAAP GROSS PROFIT AND MARGIN PERCENTAGE | |||||||||||||||||
| As Reported | |||||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||||
| September 30, 2024 | September 30, 2023 | September 30, 2024 | September 30, 2023 | ||||||||||||||
| Gross profit | $ | 23,261 | $ | 11,154 | $ | 62,357 | $ | 37,093 | |||||||||
| Amortization of acquired intangible assets | 555 | 2,800 | 3,051 | 8,400 | |||||||||||||
| Depreciation and amortization | 1,445 | 333 | 3,435 | 991 | |||||||||||||
| Stock-based compensation expense | 364 | 188 | 897 | 648 | |||||||||||||
| Cost of sales adjustment | — | — | (1,812 | ) | — | ||||||||||||
| Non-GAAP gross profit | $ | 25,625 | $ | 14,475 | $ | 67,928 | $ | 47,132 | |||||||||
| Gross margin percentage | 51.7 | % | 44.0 | % | 48.8 | % | 47.5 | % | |||||||||
| Amortization of acquired intangible assets | 1.2 | % | 11.0 | % | 2.4 | % | 10.7 | % | |||||||||
| Depreciation and amortization | 3.2 | % | 1.3 | % | 2.7 | % | 1.3 | % | |||||||||
| Stock-based compensation expense | 0.8 | % | 0.7 | % | 0.7 | % | 0.8 | % | |||||||||
| Cost of sales adjustment | 0.0 | % | 0.0 | % | (1.4 | )% | 0.0 | % | |||||||||
| Non-GAAP gross margin percentage | 56.9 | % | 57.0 | % | 53.2 | % | 60.3 | % | |||||||||
| Non-GAAP Pro Forma Combined | |||||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||||
| September 30, 2024 | September 30, 2023 | September 30, 2024 | September 30, 2023 | ||||||||||||||
| Gross profit | $ | 23,261 | $ | 20,138 | $ | 60,942 | $ | 61,924 | |||||||||
| Amortization of acquired intangible assets | 555 | 3,355 | 3,051 | 10,067 | |||||||||||||
| Depreciation and amortization | 1,445 | 760 | 3,435 | 2,150 | |||||||||||||
| Stock-based compensation expense | 364 | 260 | 897 | 816 | |||||||||||||
| Cost of sales adjustment | — | — | — | (1,337 | ) | ||||||||||||
| Non-GAAP gross profit | $ | 25,625 | $ | 24,513 | $ | 68,325 | $ | 73,620 | |||||||||
| Gross margin percentage | 51.7 | % | 42.5 | % | 47.5 | % | 43.9 | % | |||||||||
| Amortization of acquired intangible assets | 1.2 | % | 7.1 | % | 2.4 | % | 7.1 | % | |||||||||
| Depreciation and amortization | 3.2 | % | 1.6 | % | 2.7 | % | 1.5 | % | |||||||||
| Stock-based compensation expense | 0.8 | % | 0.5 | % | 0.7 | % | 0.6 | % | |||||||||
| Cost of sales adjustment | 0.0 | % | 0.0 | % | 0.0 | % | (0.9 | )% | |||||||||
| Non-GAAP gross margin percentage | 56.9 | % | 51.7 | % | 53.3 | % | 52.2 | % | |||||||||
| STANDARD BIOTOOLS INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (In thousands) (Unaudited) | |||||||||||||||||
| ITEMIZED RECONCILIATION OF GAAP TO NON-GAAP OPERATING EXPENSES | |||||||||||||||||
| As Reported | |||||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||||
| September 30, 2024 | September 30, 2023 | September 30, 2024 | September 30, 2023 | ||||||||||||||
| Operating expenses | $ | 54,979 | $ | 32,326 | $ | 204,776 | $ | 92,307 | |||||||||
| Restructuring and related charges | (2,341 | ) | (1,998 | ) | (12,374 | ) | (5,415 | ) | |||||||||
| Transaction and integration expenses | (5,079 | ) | (1,666 | ) | (25,024 | ) | (1,666 | ) | |||||||||
| Stock-based compensation expense | (5,557 | ) | (3,198 | ) | (23,365 | ) | (9,000 | ) | |||||||||
| Amortization of acquired intangible assets | (161 | ) | - | (482 | ) | - | |||||||||||
| Depreciation and amortization | (1,986 | ) | (853 | ) | (5,940 | ) | (1,883 | ) | |||||||||
| Gain/loss on disposal of property and equipment | (30 | ) | - | (415 | ) | (73 | ) | ||||||||||
| Non-GAAP operating expenses | $ | 39,825 | $ | 24,611 | $ | 137,176 | $ | 74,270 | |||||||||
| R&D operating expenses | $ | 13,156 | $ | 6,370 | $ | 48,358 | $ | 19,039 | |||||||||
| Stock-based compensation expense | (724 | ) | (459 | ) | (4,480 | ) | (1,241 | ) | |||||||||
| Depreciation and amortization | (947 | ) | (120 | ) | (2,606 | ) | (401 | ) | |||||||||
| Non-GAAP R&D operating expenses | $ | 11,485 | $ | 5,791 | $ | 41,272 | $ | 17,397 | |||||||||
| SG&A operating expenses | $ | 34,403 | $ | 22,292 | $ | 119,020 | $ | 66,187 | |||||||||
| Stock-based compensation expense | (4,833 | ) | (2,739 | ) | (18,885 | ) | (7,759 | ) | |||||||||
| Amortization of acquired intangible assets | (161 | ) | - | (482 | ) | - | |||||||||||
| Depreciation and amortization | (1,039 | ) | (733 | ) | (3,334 | ) | (1,482 | ) | |||||||||
| Gain/loss on disposal of property and equipment | (30 | ) | - | (415 | ) | (73 | ) | ||||||||||
| Non-GAAP SG&A operating expenses | $ | 28,340 | $ | 18,820 | $ | 95,904 | $ | 56,873 | |||||||||
| Non-GAAP Pro Forma Combined | |||||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||||
| September 30, 2024 | September 30, 2023 | September 30, 2024 | September 30, 2023 | ||||||||||||||
| Operating expenses | $ | 54,979 | $ | 67,431 | $ | 208,149 | $ | 214,710 | |||||||||
| Restructuring and related charges | (2,341 | ) | (1,998 | ) | (12,374 | ) | (6,515 | ) | |||||||||
| Transaction and integration expenses | (5,079 | ) | (5,823 | ) | (35,193 | ) | (5,823 | ) | |||||||||
| Stock-based compensation expense | (5,557 | ) | (4,668 | ) | (16,519 | ) | (20,335 | ) | |||||||||
| Amortization of acquired intangible assets | (161 | ) | (161 | ) | (482 | ) | (482 | ) | |||||||||
| Depreciation and amortization | (1,986 | ) | (2,110 | ) | (5,940 | ) | (5,774 | ) | |||||||||
| Gain/loss on disposal of property and equipment | (30 | ) | - | (415 | ) | (122 | ) | ||||||||||
| Non-GAAP operating expenses | $ | 39,825 | $ | 52,671 | $ | 137,226 | $ | 175,659 | |||||||||
| R&D operating expenses | $ | 13,156 | $ | 14,753 | $ | 49,010 | $ | 47,484 | |||||||||
| Stock-based compensation expense | (724 | ) | (964 | ) | (4,480 | ) | (2,476 | ) | |||||||||
| Depreciation and amortization | (947 | ) | (540 | ) | (2,606 | ) | (1,592 | ) | |||||||||
| Non-GAAP R&D operating expenses | $ | 11,485 | $ | 13,249 | $ | 41,924 | $ | 43,416 | |||||||||
| SG&A operating expenses | $ | 34,403 | $ | 44,857 | $ | 111,572 | $ | 154,888 | |||||||||
| Stock-based compensation expense | (4,833 | ) | (3,704 | ) | (12,039 | ) | (17,859 | ) | |||||||||
| Amortization of acquired intangible assets | (161 | ) | (161 | ) | (482 | ) | (482 | ) | |||||||||
| Depreciation and amortization | (1,039 | ) | (1,570 | ) | (3,334 | ) | (4,182 | ) | |||||||||
| Gain/loss on disposal of property and equipment | (30 | ) | - | (415 | ) | (122 | ) | ||||||||||
| Non-GAAP SG&A operating expenses | $ | 28,340 | $ | 39,422 | $ | 95,302 | $ | 132,243 | |||||||||
| STANDARD BIOTOOLS INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (In thousands) (Unaudited) | |||||||||||||||||
| ITEMIZED RECONCILIATION OF GAAP NET LOSS TO NON-GAAP ADJUSTED EBITDA | |||||||||||||||||
| As Reported | |||||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||||
| September 30, 2024 | September 30, 2023 | September 30, 2024 | September 30, 2023 | ||||||||||||||
| Net loss | $ | (26,938 | ) | $ | (20,997 | ) | $ | (104,813 | ) | $ | (54,880 | ) | |||||
| Income tax expense (benefit) | 118 | 50 | 301 | 614 | |||||||||||||
| Interest income, net | (3,941 | ) | (340 | ) | (13,559 | ) | (656 | ) | |||||||||
| Amortization of acquired intangible assets | 716 | 2,800 | 3,533 | 8,400 | |||||||||||||
| Depreciation and amortization | 3,431 | 1,186 | 9,375 | 2,874 | |||||||||||||
| Bargain purchase gain | — | — | (25,213 | ) | — | ||||||||||||
| Restructuring and related charges | 2,341 | 1,998 | 12,374 | 5,415 | |||||||||||||
| Transaction and integration expenses | 5,079 | 1,666 | 25,024 | 1,666 | |||||||||||||
| Stock-based compensation expense | 5,921 | 3,386 | 24,262 | 9,648 | |||||||||||||
| Cost of sales adjustment | — | — | (1,812 | ) | — | ||||||||||||
| Gain/loss on disposal of property and equipment | 30 | — | 415 | 73 | |||||||||||||
| Other non-operating expense | (957 | ) | 115 | 865 | (292 | ) | |||||||||||
| Adjusted EBITDA | (14,200 | ) | (10,136 | ) | (69,248 | ) | (27,138 | ) | |||||||||
| Non-GAAP Pro Forma Combined | |||||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||||
| September 30, 2024 | September 30, 2023 | September 30, 2024 | September 30, 2023 | ||||||||||||||
| Net loss | $ | (26,938 | ) | $ | (41,204 | ) | $ | (134,607 | ) | $ | (109,000 | ) | |||||
| Income tax expense (benefit) | 118 | 528 | 301 | 1,096 | |||||||||||||
| Interest income, net | (3,941 | ) | (6,447 | ) | (13,559 | ) | (17,604 | ) | |||||||||
| Amortization of acquired intangible assets | 716 | 3,516 | 3,533 | 10,549 | |||||||||||||
| Depreciation and amortization | 3,431 | 2,870 | 9,375 | 7,924 | |||||||||||||
| Bargain purchase gain | — | — | — | (25,213 | ) | ||||||||||||
| Restructuring and related charges | 2,341 | 1,998 | 12,374 | 6,515 | |||||||||||||
| Transaction and integration expenses | 5,079 | 5,823 | 35,193 | 5,823 | |||||||||||||
| Stock-based compensation expense | 5,921 | 4,928 | 17,416 | 21,151 | |||||||||||||
| Cost of sales adjustment | — | — | — | (1,337 | ) | ||||||||||||
| Gain/loss on disposal of property and equipment | 30 | — | 415 | 122 | |||||||||||||
| Other non-operating expense | (957 | ) | (170 | ) | 658 | (2,065 | ) | ||||||||||
| Adjusted EBITDA | (14,200 | ) | (28,158 | ) | (68,901 | ) | (102,039 | ) | |||||||||
FAQ
What was Standard BioTools (LAB) revenue in Q3 2024?
How much did Standard BioTools (LAB) improve its EBITDA in Q3 2024?
What is Standard BioTools (LAB) revenue guidance for full year 2024?
How much cash does Standard BioTools (LAB) have as of September 30, 2024?
